Regulatory Perspectives for Phytochemicals and Their Clinical Translation

Bioactive substances called phytochemicals, which are produced from plants, are well-known to have anti-inflammatory, anticancer, cardioprotective, neuroprotective, antibacterial, and immunomodulatory effects. These effects have been highlighted in ancient literature. Preclinical research offers vital details about their pharmacokinetics, pharmacodynamics, and safety profiles in urological cancers via in vitro tests and in vivo animal models. But translating the preclinical data results into clinical use remains challenging due to variability in plant sources, problems with standardization and quality control, low bioavailability, stability issues, and possible herb–drug interactions. Regional regulatory frameworks vary greatly as the European Medicines Agency regulates traditional herbal medicinal products under the Traditional Herbal Medicinal Products Directive; the United States Food and Drug Administration provides guidance for dietary supplements and botanical drugs; India regulates through the Central Drugs Standard Control Organisation and AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy) pathways; and international standards, such as the World Health Organization (WHO) guidelines, seek to standardize safety and efficacy requirements. This book chapter highlights the significance of stringent clinical trials, standardized manufacturing procedures, and well-defined regulatory channels in assuring the secure and efficient use of phytochemicals into urological cancer.